Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Banco Santander S.A.

Banco Santander S.A. lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,664 shares of the life sciences company’s stock after selling 600 shares during the period. Banco Santander S.A.’s holdings in Illumina were worth $2,761,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Versant Capital Management Inc increased its holdings in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the last quarter. Golden State Wealth Management LLC purchased a new stake in Illumina during the fourth quarter valued at about $32,000. Assetmark Inc. increased its stake in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina in the 4th quarter worth about $45,000. Finally, TD Private Client Wealth LLC raised its holdings in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ILMN. Citigroup dropped their target price on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada decreased their price objective on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Morgan Stanley cut their target price on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Canaccord Genuity Group decreased their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, February 7th. Finally, TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and cut their price objective for the company from $177.00 to $140.00 in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $149.25.

Illumina Trading Up 2.3 %

Shares of NASDAQ ILMN opened at $86.62 on Friday. The company has a market cap of $13.72 billion, a price-to-earnings ratio of -11.28, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The stock’s 50 day simple moving average is $118.38 and its 200 day simple moving average is $131.49. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $80.18 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.